TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05941091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HafifMod Programme
Description: MODULAR EDUCATION PROGRAMME: A training program consisting of five modules, shaped by the main headings of fluid and salt control in hemodialysis patients, was created. It is aimed that the patients receive training on a topic each week in a gradual manner. It will be ensured that HD patients can watch the modular training videos prepared in the computer environment on a tablet or computer.~MOBİLE APPLICATION: Through the mobile application to be developed, the maximum amount of fluid that HD patients should consume per day will be calculated automatically based on their dry weight. In addition, a system will be created where the user can manually enter the amount of fluid consumed daily and add it to the total amount of fluid consumed. In this way, people will be able to learn the amount of fluid they consume daily. In addition, the content of the application will include informative messages in the form of educational short tips and modular training videos.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Distribution of printed material
Description: In the study, a general dietary guideline including fluid and salt restriction, which is a printed educational material for the control group, will be used. Thus, it is planned that the participants in the control group will have a guide resource that will enable them to be informed about nutrition. In this way, an educational practice based on the distribution of printed material will be carried out for the control group. Except for the material distribution practice, the routine care procedures the unit will be maintained in the same way, and no different a practice will be made.
Study: NCT06397469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MediTrain
Description: MediTrain is a tablet-based, meditation-inspired, cognitive training game aimed at improving self-regulation of internal attention and distractions. It was developed in collaboration with meditation thought-leader Jack Kornfield, and Zynga, a world-class video game company. It was created to make benefits of concentrative meditation more easily accessible to anyone, including complete novices. This is achieved by creating a game that yields quantifiable and attainable goals, provides feedback, and includes an adaptive algorithm to gradually increase difficulty as users improve.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MediTrain
Description: MediTrain is a tablet-based, meditation-inspired, cognitive training game aimed at improving self-regulation of internal attention and distractions. It was developed in collaboration with meditation thought-leader Jack Kornfield, and Zynga, a world-class video game company. It was created to make benefits of concentrative meditation more easily accessible to anyone, including complete novices. This is achieved by creating a game that yields quantifiable and attainable goals, provides feedback, and includes an adaptive algorithm to gradually increase difficulty as users improve.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MediTrain
Description: MediTrain is a tablet-based, meditation-inspired, cognitive training game aimed at improving self-regulation of internal attention and distractions. It was developed in collaboration with meditation thought-leader Jack Kornfield, and Zynga, a world-class video game company. It was created to make benefits of concentrative meditation more easily accessible to anyone, including complete novices. This is achieved by creating a game that yields quantifiable and attainable goals, provides feedback, and includes an adaptive algorithm to gradually increase difficulty as users improve.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MediTrain
Description: MediTrain is a tablet-based, meditation-inspired, cognitive training game aimed at improving self-regulation of internal attention and distractions. It was developed in collaboration with meditation thought-leader Jack Kornfield, and Zynga, a world-class video game company. It was created to make benefits of concentrative meditation more easily accessible to anyone, including complete novices. This is achieved by creating a game that yields quantifiable and attainable goals, provides feedback, and includes an adaptive algorithm to gradually increase difficulty as users improve.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Worder
Description: Worder was designed to enhance visual motor and visual spatial skills in individuals of all ages and cognitive abilities. Visual processing is required for all cognitive abilities that involve vision including attention, working memory, and task management. Worder's goal is to improve cognitive function more broadly by developing this critical skill underlying multiple abilities.
Study: NCT06369350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B6 25 MG
Description: Vitamin B6 25 mg/day will be given for up to 31 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B6 50 MG
Description: Vitamin B6 50 mg/day will be given for up to 31 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B6 100 MG
Description: Vitamin B6 100 mg/day will be given for up to 31 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule will be given for up to 31 days.
Study: NCT05860699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo made by the same manufacturer to look like the active pills

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Half dose CBD
Description: add-on cannabidiol (Echo Pharmaceutical, BV) 450 mg per day for 10 days during their inpatient stay

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Full dose CBD
Description: add-on cannabidiol (Echo Pharmaceutical, BV) 900 mg per day for 10 days during their inpatient stay
Study: NCT04680000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BCBT-CP Booster
Description: The BCBT-CP Booster is a telephone or videoteleconference-based booster contact designed to extend the benefits of the standard of care BCBT-CP intervention. BCBT-CP Booster contacts are not clinical interventions (i.e., no new clinical content is provided), but are intended to help motivate patients to use BCBT-CP module content, problem-solve BCBT-CP skills practice and offer reminders for future appointments. BCBT-CP Booster content was developed using feedback from focus groups with patients who completed standard BCBT-CP treatment in a military primary care clinic. Details on BCBT-CP Booster contacts can be found in the treatment arm description section of this listing.
Study: NCT04994210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 1. To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of newly diagnosed ENKTCL patients~2. To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of newly diagnosed ENKTCL patients.~3. Exploring biomarkers that may have predictive effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 1. To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of newly diagnosed ENKTCL patients~2. To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of newly diagnosed ENKTCL patients.~3. Exploring biomarkers that may have predictive effects.
Study: NCT05003804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STMC-103H
Description: STMC-103H is a live biotherapeutic product (LBP) containing a consortium of intestinal bacteria

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STMC-103H
Description: STMC-103H is a live biotherapeutic product (LBP) containing a consortium of intestinal bacteria

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STMC-103H
Description: STMC-103H is a live biotherapeutic product (LBP) containing a consortium of intestinal bacteria

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder containing excipients found in STMC-103H: magnesium stearate, mannitol and silicon dioxide.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder containing excipients found in STMC-103H: magnesium stearate, mannitol and silicon dioxide.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder containing excipients found in STMC-103H: magnesium stearate, mannitol and silicon dioxide.
Study: NCT05284331

Intervention type: OTHER
Group type: OTHER
Intervention: addition of two follow-up visits post infection
Description: Addition of an additional follow-up visit 6 months post infection and one follow-up visit 1 year post infection.~No treatment will be given specifically for this study. The change in medical management will only be modified by the addition of these 2 consultations at 6 months and 1 year post infection
Study: NCT05473832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day Cream cosmetic product compared to untreated side
Description: Applied once daily in the morning

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Night cream cosmetic product compared to untreated side
Description: Applied once daily in the evening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye cream cosmetic product compared to untreated side
Description: Applied twice daily in the morning and in the evening around the eye area

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serum cosmetic product compared to untreated side
Description: Applied twice daily in the morning and in the evening
Study: NCT04902040

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT06415383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B6 100 MG
Description: Vitamin B6 in for the form of pyridoxal phosphate (PLP)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet containing microcrystalline cellulose
Study: NCT05290558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bu Shen Yi Jing Pill
Description: Bu Shen Yi Jing Pill contained Radix Pseudostellaria, Fructus Lycii, Radix Et Rhizoma Salviae, Rhizoma Dioscorea, Semen Plantaginis, Semen Cuscuta, Patriniae Herba, Herba Epimedii, Radix Ophiopogonis, Fructus Rubi, Fructus Corni, Bupleurum roots, Fructus Schisandrae Chinensis, Radix Et Rhizoma Glycyrrhizae.~Dosage of the study drug is as follows: 3 pills each time, for 3 times a day, taken for 6 days every week for 1 year
Study: NCT05610254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: On the first trial day healthy volunteers are randomized to receive 30 ml/kg of Ringer's lactate either cold (15°C, 59°F), or at body temperature (37°C, 98.6°F) during a 30-minute interval. After a minimum washout period of 24 hours, subjects are switched to receive infusion at the other aforementioned temperatures.
Study: NCT05290558

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Drug
Description: Placebo contains the ingredients: grounded black rice and permitted colouring. The ingredients are encapsulated within a gelatine capsule.~Dosage of the study drug is as follows: 3 pills each time, for 3 times a day, taken for 6 days every week for 1 year
Study: NCT05382819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FRTX-02 Capsule
Description: DYRK-1A Inhibitor
Study: NCT05450965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: Onvansertib at a dose of 15 mg/m2 orally on Days 1-14 of a 21-day cycle. Treatment will continue until disease progression or intolerable toxicity.
Study: NCT05382819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FRTX-02 Capsule
Description: DYRK-1A Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FRTX-02 Capsule
Description: DYRK-1A Inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT04798053

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: 14-item Perceived Stress Scale (PSS-14), 9-item Patient Health Questionnaire (PHQ-9 questionnaire), State Trait Inventory Anxiety questionnaire (STAI questionnaire), Post-traumatic Stress Disorder Checklist Scale (PCL-S questionnaire)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: 14-item Perceived Stress Scale (PSS-14), 9-item Patient Health Questionnaire (PHQ-9 questionnaire), State Trait Inventory Anxiety questionnaire (STAI questionnaire), Post-traumatic Stress Disorder Checklist Scale (PCL-S questionnaire)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample and salivary sample
Description: 10 ml whole blood for Peripheral blood and 2 ml saliva sample. Only for 100 cases.
Study: NCT05557942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-101
Description: AV-101 (imatinib) administered via dry powder inhalation
Study: NCT04967482

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drug-eluting bead transarterial chemoembolization (DEB-TACE)
Description: The patients will receive DEB-TACE if they choose DEB-TACE as the primary treatment. DC Bead loaded with epirubicin (1 vial of DC Bead loaded with 60 mg of epirubicin) is used for chemoembolization. During follow-up, TACE will be repeated on demand based on the evaluation of the follow-up laboratory and imaging examination, and the technique method of each TACE procedure (i.e. DEB-TACE) for the same patient should be consistent.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional transarterial chemoembolization (cTACE)
Description: The patients will receive cTACE if they choose cTACE as the primary treatment. An emulsion of epirubicin in lipiodol wiil be injected into the tumor feeding artery. Afterwards, microspheres or polyvinyl alcohol particles mixed with contrast agent will be administered intraarterially until arterial flow stasis was achieved. Generally, the dose of lipiodol and epirubicin should not exceed 30 mL and 60 mg for each procedure. During follow-up, TACE will be repeated on demand based on the evaluation of the follow-up laboratory and imaging examination, and the technique method of each TACE procedure (i.e. cTACE) for the same patient should be consistent.
Study: NCT05557942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-101
Description: AV-101 (imatinib) administered via dry powder inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-101
Description: AV-101 (imatinib) administered via dry powder inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-101
Description: AV-101 (imatinib) administered via dry powder inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-101
Description: AV-101 (imatinib) administered via dry powder inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-101
Description: AV-101 (imatinib) administered via dry powder inhalation
Study: NCT05274243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-HOBA
Description: 2-HOBA acetate (2-Hydroxybenzlamine acetate) 750mg (provided as three 250mg capsules) three times per day for 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (provided as three capsules) three times a day for 4 weeks
Study: NCT05663073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan/Amlodipine FDC
Description: Irbesartan/Amlodipine FDC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: Co-administration of Irbesartan and Amlodipine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Co-administration of Irbesartan and Amlodipine
Study: NCT05626400

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Senl-T7
Description: Patients will be treated with CD7 CAR-T cells
Study: NCT06142357

Intervention type: OTHER
Intervention: Secukinumab
Description: There is no treatment allocation. Patients administered secukinumab by prescription will be enrolled
Study: NCT05952141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic Outreach
Description: A member of the pathology team will contact the referring clinic to communicate the readiness of results.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic Outreach
Description: A member of the pathology team will contact the referring clinic to communicate the readiness of results.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Outreach
Description: A member of the pathology team will contact both the referring clinic and the patient directly to communicate the readiness of results.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Outreach
Description: A member of the pathology team will contact both the referring clinic and the patient directly to communicate the readiness of results.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-Touch Strategy
Description: Patient will be sent asynchronous text messaging reminders related to the importance of timely care using framed messaging.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-Touch Strategy
Description: Patient will be sent asynchronous text messaging reminders related to the importance of timely care using framed messaging.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Touch Strategy
Description: Patient will be sent asynchronous text messaging reminders related to the importance of timely care using framed messaging in combination with synchronous telephone-based patient navigation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Touch Strategy
Description: Patient will be sent asynchronous text messaging reminders related to the importance of timely care using framed messaging in combination with synchronous telephone-based patient navigation.
Study: NCT05565781

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECG smartwatch
Description: Testing ECG smartwatch

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insertable Cardiac Monitor (ICM)
Description: Gold-standard cardiac monitor for comparison of testing device (ECG smartwatch)

Intervention type: DEVICE
Group type: OTHER
Intervention: External ECG Monitoring
Description: Regular cardiac monitor for diagnosis of atrial fibrillation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External ECG Monitoring
Description: Regular cardiac monitor for diagnosis of atrial fibrillation
Study: NCT06440239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMS-101
Description: PMS-101

Intervention type: OTHER
Group type: OTHER
Intervention: Standard treatment
Description: Standard treatment according to physicians
Study: NCT06438783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1200mg of TQB2928 injection+Anlotinib
Description: TQB2928 is a novel humanized immunoglobulin G4 (IgG4) subtype monoclonal antibody targeting Cluster of Differentiation 47 (CD47).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1800mg of TQB2928 injection+Anlotinib
Description: TQB2928 is a novel humanized igG4 subtype monoclonal antibody targeting CD47.
Study: NCT05661877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DengueAid mobile application
Description: •Education materials regarding dengue fever and self-care. The education section (My Dengue Knowledge) consists of seven modules (dengue essentials, risk, symptoms, aedes mosquito, self-care, prevention and interesting facts) with gamification properties. Each module contains a series of multiple-choice questions. After answering each question, the user would be instantly notified if they had answered the question correctly and be provided with some facts related to the question. A progress meter would allow users to keep track of each module answered. A medal would be awarded to users who have completed 100% of each module. The self-care section consists of basic information about dengue fever and points to look out for self-care. It contains information on dengue fever phases, signs of dengue, importance of keeping hydrated, complementary therapy, medicine to avoid and prevention practices.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MyHealth website
Description: MyHealth is developed by Ministry of Health, Malaysia (http://www.myhealth.gov.my/en/dengue-fever/) to provide information on dengue.
Study: NCT06405776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: Patients in the lidocaine group, lidocaine 1.5mg/kg/h is continuously infused (using ideal body weight) during the whole procedure, postoperative analgesia pump with lidocaine (lidocaine 50mg/kg, sufentanil 2ug/kg, glassetron 12mg) diluted to 200ml with saline until 72h after surgery.
Study: NCT06370676

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Oesophageal temperature measurement
Description: Oesophageal temperature measurement

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Oesophageal temperature measurement
Description: Oesophageal temperature measurement

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oesophageal temperature measurement
Description: Oesophageal temperature measurement

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oesophageal temperature measurement
Description: Oesophageal temperature measurement
Study: NCT05136105

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventive Narrative Exposure Therapy (PreNET) family intervention
Description: Sessions: (1) Participants are invited to narrate the event in detail, in line with the protocol of the trauma-focused intervention NET. Furthermore, participants and caregiver(s) will receive a brief psychoeducation about expected symptoms and supportive behaviour in the aftermath of sexual violence.~(2) Two weeks after session 1, the second session focuses on caregiver only and their emotions. The narration of the event is read to the caregiver(s). Caregiver(s) receive assistance regulating their emotions. They receive psychoeducation on how to support their child.~(3) Two weeks after the second session, the children assisted by their caregivers lay a chronological lifeline of their most important life experiences. The chronology and the context of the traumatic events is reinforced. The narration of the sexual abuse is read again to the child and the caregiver(s). The caregiver(s) are encouraged to support emotionally their child during the renarration.